Aytu Biopharma (AYTU) Interest Expenses (2010 - 2026)

Aytu Biopharma (AYTU) has 17 years of Interest Expenses data on file, last reported at $20.7 million in Q1 2026.

• On a quarterly basis, Interest Expenses rose 315.03% year-over-year to $20.7 million in Q1 2026; TTM through Mar 2026 was $20.7 million, a 315.03% increase from a year earlier, with the FY2025 full-year figure at $136.6 million, changed 0.47% from the prior year.
• Interest Expenses for Q1 2026 stood at $20.7 million, roughly flat from $20.7 million in the prior quarter.
• Over the last five years, Interest Expenses for AYTU reached as high as $194.3 million in Q1 2023 and fell as low as -$465.1 million in Q2 2023.
• Historically, Interest Expenses has averaged -$1.4 million across 5 years, with a median of $20.7 million in 2026.
• Across the five-year window, Interest Expenses soared 1274.0% in 2022 and sank 17024.6% in 2023, its largest moves.
• Year by year, Interest Expenses stood at $33.0 million in 2022, then sank by 84.91% to $5.0 million in 2023, then soared by 394.39% to $24.7 million in 2024, then fell by 16.03% to $20.7 million in 2025, then decreased by 0.0% to $20.7 million in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $20.7 million in Q1 2026, $20.7 million in Q4 2025, and $20.7 million in Q3 2025.